A new study from researchers at the University of Texas Southwestern Medical Center in Dallas found no major long-term differences in the effectiveness of radiation therapy versus surgery in treating oropharyngeal squamous cell carcinoma (OPSCC). Given these results, investigators suggest quality-of-life factors should help inform a treatment decision. The findings compared the effectiveness of definitive […]
Experts Discuss HPV-Positive Head and Neck Cancer
De-intensifying both surgical and radiation treatment can be effective in some patients
Larynx-Preserving Surgery Associated with Improved Survival in Early-Stage Glottic Cancer
Larynx-preserving surgery alone and larynx-preserving surgery with radiation were associated with improved survival compared to radiation alone.
Fanconi Anemia Patients with HNSCC Tolerate Surgery Better than Radiation, Chemotherapy
The treatment of FA-associated HNSCC is difficult secondary to the poor tolerance of radiation and chemotherapy
Primary Radiation vs. Primary Surgical Therapy for Cervical Esophageal Cancer
What is the best initial therapy for patients requiring treatment of cervical esophageal cancer?
New Treatment for Head and Neck Cancer Means Longer-Lasting Toxicity
Better chemotherapy and aggressive chemoradiation have contributed to improved locoregional control and survival for head and neck cancer.
Induction Chemotherapy for Base of Tongue Cancer Under Study
Stereotactic Radiation an Option for Acoustic Neuromas But Hearing Loss a Risk
Although stereotactic radiation provides a noninvasive approach to treating acoustic neuromas, it also carries the risk of hearing loss over time for a sizable portion of patients, according to experts.
Selecting the Right Patients Is Key for Chemoradiation Success
Head and neck cancer care has been undergoing a paradigm shift over the past decade, moving from a surgery-based approach to one that increasingly relies on chemoradiation (CRT).
Targeted Therapies + Chemo Show Activity in Recurrent/Metastatic Head And Neck Cancer
The targeted therapies erlotinib and cetuximab, in combination with standard chemotherapy regimens, are well tolerated and have very encouraging activity in recurrent/metastatic head and neck squamous cell carcinoma, according to two presentations at the American Society of Clinical Oncology (ASCO) 2007 Annual Meeting in Chicago.